이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Guangzhou Baiyunshan Pharmaceutical Holdings 배당금
배당금 기준 확인 4/6
Guangzhou Baiyunshan Pharmaceutical Holdings 수익으로 충분히 충당되는 현재 수익률 3.75% 보유한 배당금 지급 회사입니다.
주요 정보
3.9%
배당 수익률
30%
지급 비율
| 업계 평균 수익률 | 3.7% |
| 다음 배당금 지급일 | n/a |
| 전 배당일 | n/a |
| 주당 배당금 | n/a |
| 주당 순이익 | HK$2.53 |
| 3년 후 배당 수익률 예측 | 4.5% |
최근 배당금 업데이트
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Recent updates
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26결제의 안정성과 성장
배당금 데이터 가져오기
안정적인 배당: 874 의 배당금 지급은 지난 10 년 동안 휘발성이었습니다.
배당금 증가: 874 의 배당금 지급은 지난 10 년 동안 증가했습니다.
시장 대비 배당 수익률
| Guangzhou Baiyunshan Pharmaceutical Holdings 시장 대비 배당 수익률 |
|---|
| 세그먼트 | 배당 수익률 |
|---|---|
| 회사 (874) | 3.9% |
| 시장 하위 25% (HK) | 3.4% |
| 시장 상위 25% (HK) | 7.9% |
| 업계 평균 (Healthcare) | 3.7% |
| 3년 후 애널리스트 예측 (874) | 4.5% |
주목할만한 배당금: 874 의 배당금( 3.75% )은 Hong Kong 시장에서 배당금 지급자의 하위 25%( 3.2% )보다 높습니다. 3.2% ).
고배당: 874 의 배당금( 3.75% )은 Hong Kong 시장에서 배당금 지급자의 상위 25% 7.75% ).
주주에 대한 수익 배당금
수익 보장: 합리적으로 낮은 지불 비율 ( 29.7% )로 874 의 배당금 지급은 수익으로 충분히 충당됩니다.
주주에 대한 현금 배당금
현금 흐름 범위: 합리적인 현금 지급 비율 ( 58.2% )로 874 의 배당금 지급은 현금 흐름으로 충당됩니다.